Freeze-drying for the Preservation of Immunoengineering Products

Overview

Journal iScience

Publisher Cell Press

Date 2022 Oct 21

PMID 36267916

Authors

Nagavendra Kommineni

Arun Butreddy

Vaskuri G S Sainaga Jyothi

Pavimol Angsantikul

Affiliations

Soon will be listed here.

Abstract

Immunoengineering technologies harness the power of immune system modulators such as monoclonal antibodies, cytokines, and vaccines to treat myriad diseases. Immunoengineering innovations have showed great promise in various practices including oncology, infectious disease, autoimmune diseases, and transplantation. Despite the countless successes, the majority of immunoengineering products contain active moieties that are prone to instability. The current review aims to feature freeze-drying as a robust and scalable solution to the inherent stability challenges in immunoengineering products by preventing the active moiety from degradation. Furthermore, this review describes the stability issues related to immunoengineering products and the utility of the lyophilization process to preserve the integrity and efficacy of immunoengineering tools ranging from biologics to nanoparticle-based vaccines. The concept of the freeze-drying process is described highlighting the quality by design (QbD) for robust process optimization. Case studies of lyophilized immunoengineering technologies and relevant clinical studies using immunoengineering products are discussed.

Citing Articles

Practical advice in the development of a lyophilized protein drug product.

Cheng Y, Duong H, Hu Q, Shameem M, Tang X Antib Ther. 2025; 8(1):13-25.

PMID: 39839910 PMC: 11744310. DOI: 10.1093/abt/tbae030.

Brief Insights into mRNA Vaccines: Their Successful Production and Nanoformulation for Effective Response against COVID-19 and Their Potential Success for Influenza A and B.

Parveen A, Elkordy A Pathogens. 2024; 13(6).

PMID: 38921798 PMC: 11206352. DOI: 10.3390/pathogens13060500.

Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry.

Rahban M, Ahmad F, Piatyszek M, Haertle T, Saso L, Saboury A RSC Adv. 2023; 13(51):35947-35963.

PMID: 38090079 PMC: 10711991. DOI: 10.1039/d3ra06476j.

Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine.

Li M, Jia L, Xie Y, Ma W, Yan Z, Liu F NPJ Vaccines. 2023; 8(1):153.

PMID: 37813912 PMC: 10562438. DOI: 10.1038/s41541-023-00732-9.

References

Feng J, Zhang Y, McManus S, Qian R, Ristroph K, Ramachandruni H . Amorphous nanoparticles by self-assembly: processing for controlled release of hydrophobic molecules. Soft Matter. 2019; 15(11):2400-2410. DOI: 10.1039/c8sm02418a. View

Musial-Wysocka A, Kot M, Majka M . The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019; 28(7):801-812. PMC: 6719501. DOI: 10.1177/0963689719837897. View

Ward K, Matejtschuk P . The Principles of Freeze-Drying and Application of Analytical Technologies. Methods Mol Biol. 2020; 2180:99-127. DOI: 10.1007/978-1-0716-0783-1_3. View

Jovanovic N, Bouchard A, Hofland G, Witkamp G, Crommelin D, Jiskoot W . Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying. Eur J Pharm Sci. 2005; 27(4):336-45. DOI: 10.1016/j.ejps.2005.11.003. View

Lajnaf R, Picart-Palmade L, Attia H, Marchesseau S, Ayadi M . Foaming and adsorption behavior of bovine and camel proteins mixed layers at the air/water interface. Colloids Surf B Biointerfaces. 2016; 151:287-294. DOI: 10.1016/j.colsurfb.2016.12.010. View

Conlon K, Miljkovic M, Waldmann T . Cytokines in the Treatment of Cancer. J Interferon Cytokine Res. 2018; 39(1):6-21. PMC: 6350412. DOI: 10.1089/jir.2018.0019. View

Oyewumi M, Kumar A, Cui Z . Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010; 9(9):1095-107. PMC: 2963573. DOI: 10.1586/erv.10.89. View

Kasper J, Friess W . The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm. 2011; 78(2):248-63. DOI: 10.1016/j.ejpb.2011.03.010. View

Xiao H, Huang L, Zhang W, Yin Z . Damage of proteins at the air/water interface: Surface tension characterizes globulin interface stability. Int J Pharm. 2020; 584:119445. DOI: 10.1016/j.ijpharm.2020.119445. View

10.

Arango Duque G, Descoteaux A . Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5:491. PMC: 4188125. DOI: 10.3389/fimmu.2014.00491. View

11.

Schneid S, Gieseler H, Kessler W, Luthra S, Pikal M . Optimization of the secondary drying step in freeze drying using TDLAS technology. AAPS PharmSciTech. 2011; 12(1):379-87. PMC: 3066362. DOI: 10.1208/s12249-011-9600-7. View

12.

Thoryk E, Swaminathan G, Meschino S, Cox K, Gindy M, Casimiro D . Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice. Vaccines (Basel). 2016; 4(4). PMC: 5192367. DOI: 10.3390/vaccines4040047. View

13.

Wang W, Nema S, Teagarden D . Protein aggregation--pathways and influencing factors. Int J Pharm. 2010; 390(2):89-99. DOI: 10.1016/j.ijpharm.2010.02.025. View

14.

Bayer V . An Overview of Monoclonal Antibodies. Semin Oncol Nurs. 2019; 35(5):150927. DOI: 10.1016/j.soncn.2019.08.006. View

15.

Butreddy A, Dudhipala N, Janga K, Gaddam R . Lyophilization of Small-Molecule Injectables: an Industry Perspective on Formulation Development, Process Optimization, Scale-Up Challenges, and Drug Product Quality Attributes. AAPS PharmSciTech. 2020; 21(7):252. DOI: 10.1208/s12249-020-01787-w. View

16.

Anamur C, Winter G, Engert J . Stability of collapse lyophilized influenza vaccine formulations. Int J Pharm. 2015; 483(1-2):131-41. DOI: 10.1016/j.ijpharm.2015.01.053. View

17.

Sundaramurthi P, Suryanarayanan R . The effect of crystallizing and non-crystallizing cosolutes on succinate buffer crystallization and the consequent pH shift in frozen solutions. Pharm Res. 2010; 28(2):374-85. DOI: 10.1007/s11095-010-0282-8. View

18.

McKeage K . Daratumumab: First Global Approval. Drugs. 2016; 76(2):275-81. DOI: 10.1007/s40265-015-0536-1. View

19.

Zapadka K, Becher F, Gomes Dos Santos A, Jackson S . Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017; 7(6):20170030. PMC: 5665799. DOI: 10.1098/rsfs.2017.0030. View

20.

Jain S, Batra H, Yadav P, Chand S . COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. Vaccines (Basel). 2020; 8(4). PMC: 7711779. DOI: 10.3390/vaccines8040649. View